Sonde Health, an advancing voice tech company, has announced a new partnership with Koye Pharmaceuticals, a company focused on the pharma market in India. The partnership aims to develop new vocal biomarkers for Chronic Obstructive Pulmonary Disease (COPD) detection and monitoring among patients in India. 

COPD is a respiratory disorder that causes breathing difficulty. According to the World Health Organization, it is the third leading cause of death worldwide. There are an estimated 30 million patients with COPD in India. The growing percentage of COPD in the country is one of the highest in the world. 

Koye will use Sonde’s vocal biomarker development platform and expand upon existing vocal biomarkers for respiration to create new ones specific to COPD patients in India. Patients in India would get a better opportunity to have their COPD tracked and treated through vocal biomarkers. This is Sonde’s first partnership with a pharma company. It’s a great way for the vocal biomarker company to take a more targeted approach. 

Although COPD has no cure, such partnerships encourage patients to monitor their condition through non-invasive methods and allow healthcare providers treat their patients in time.

Sonde Health has previously developed vocal biomarker tech for monitoring and detecting respiratory impairment, mental well-being, and mild cognitive impairment.